Company / Operating Cash Flow
Axsome Therapeutics, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$93.4M
FY2025
5-year range
-$145.1M / -$93.4M
FY2021-FY2025
Trend
+27.3%
vs FY2024
Sector context
#121 of 216
Health Care
What the data says
At -$93M, Axsome Therapeutics, Inc.'s operating cash flow ranks #121 of 216 in the Health Care sector. Improved from -$145M to -$93M over the past 2 years.
Based on SEC 10-K filings.
-$93M in FY2025.
Improved from -$145M to -$93M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#121 of 216 in Health CareTop 56% of 216This company -$93.4M Sector average $658.7M
▼
-114.2% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 27.3% year-over-year.
- Ranks #121 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2016.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$93.4M | +27.3% |
| FY2024 | -$128.4M | +11.5% |
| FY2023 | -$145.1M | -24.5% |
| FY2022 | -$116.5M | -7.7% |
| FY2021 | -$108.2M | -37.9% |
| FY2020 | -$78.5M | -69.2% |
| FY2019 | -$46.4M | -54.3% |
| FY2018 | -$30.1M | -13.5% |
| FY2017 | -$26.5M | -24.4% |
| FY2016 | -$21.3M | -186.1% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026